# Media Release

**14 June 2018**

## PHARMAXIS 'BEST IN CLASS' LOXL2 PROGRAM ATTRACTS STRONG PHARMA INTEREST AS IT ENTERS FINAL STAGE OF PHASE 1 TRIALS

- First stage of phase 1 studies demonstrate a best in class profile for lysyl oxidase like 2 (LOXL2) inhibitors with two compounds achieving significant and long lasting inhibition of LOXL2 enzyme after a single oral dose.
- Final stages of phase 1 studies and phase 2 enabling toxicity studies are due to complete in Q3 2018.
- Pharmaxis conducts multiple partnering discussions with multinational Pharma companies at BIO 2018.

Pharmaceutical research company Pharmaxis (ASX: PXS) has briefed potential partners attending the BIO18 partnering conference in Boston on data emerging from the phase 1 clinical studies of its anti-fibrotic LOXL2 inhibitor program which have demonstrated a best in class profile.

LOXL2 has been implicated as a key factor in various fibrotic diseases in organs such as the liver, lung, heart and kidney.

The two compounds have both cleared the first stage of these studies where single oral doses of different strengths were trialled in healthy volunteers. There were no adverse safety findings in this first stage. Both drugs are now entering the final stage where different fixed doses are given for 14 days. In addition to studying their safety and pharmacokinetic profiles the two studies are also investigating the degree to which these drugs can inhibit the target enzyme LOXL2. Importantly, Pharmaxis has been able to demonstrate a large and highly significant inhibition of this enzyme for a full 24 hours with a single oral dose.

Pharmaxis CEO Gary Phillips said, "The data package being reviewed by several multinational pharmaceutical companies under confidentiality agreements is now maturing rapidly as we see the final data being generated by ongoing pre-clinical and clinical studies. There are a number of key features which have contributed to an increase in the already strong interest amongst these companies. As research into predictive in vivo animal models for anti-fibrotic diseases such as NASH and IPF and their biomarkers continue, our newly developed proprietary test to measure the levels of active LOXL2 in human blood has shown we have a best in class LOXL2 inhibitor. Other LOXL2 drug programs have either shown no enzyme inhibition in humans at all or only short-lived inhibition, however both our drugs deliver high levels of inhibition for a full 24 hours from a single daily dose. This finding plus the reassuring safety profile in Phase 1 trials and toxicity studies are key to the overall positive engagement with Pharma that we expect will lead to commercial partnering discussions later this year."

The amine oxidase platform at Pharmaxis has generated small molecule enzyme inhibitors to a range of important disease targets that are at various stages of development. The SSAO inhibitor acquired by Boehringer is in phase 2 and the LOXL2 inhibitors are in phase 1 trials. Meanwhile a compound inhibiting both myeloperoxidase (MPO) and SSAO and another compound inhibiting all the LOX family of enzymes are both in the final stages of pre-clinical testing with phase 1 trials scheduled to commence in the next 6 to 12 months.

**#ends#**

**SOURCE:** Pharmaxis Ltd, Sydney, Australia
**CONTACT:** Felicity Moffatt, phone +61 418 677 701 or email felicity.moffatt@pharmaxis.com.au

**About Pharmaxis**

Pharmaxis (ACN 082 811 630) is an Australian pharmaceutical research company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval. Its product Bronchitol® for cystic fibrosis is marketed in Europe, Russia and Australia. Its product Aridol® for the assessment of asthma is sold in Europe, Australia and Asia. The company's development pipeline is centred on its expertise in amine oxidase chemistry and includes a series of Lysyl Oxidase Inhibitors under clinical development targeting fibrotic diseases of the heart, kidney, liver and lung. In May 2015, Boehringer Ingelheim acquired the Pharmaxis investigational drug PXS-4728A, a potent inhibitor of Semicarbazide-Sensitive Amine Oxidase (SSAO), to develop it for the treatment of the liver-related condition Non-alcoholic Steatohepatitis (NASH) and other inflammatory diseases. Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company's head office, manufacturing and research facilities are located in Sydney, Australia. For more information about Pharmaxis, please see www.pharmaxis.com.au

**Forward-Looking Statements**

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new informbation, future events or otherwise.